NCT04008095Completed
Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical Cancer
Evaluation of the Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical Cancer at an Advanced Stage. Multicenter Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 20 May 2026
Brief summary (registry, in English)
A lot of studies have demonstrated the prognostic value of post therapy 18F-FDG PET/CT in the management of uterine cervical cancer. Post therapy 18F-FDG PET/CT is usually requested by a lot of clinicians. Whereas 18F-FDG PET/CT is useful for prognosis in the follow-up, data are yet insufficient to clearly establish a formal recommendation. This prospective multicenter observational study will evaluate the interest of post therapy 18F-FDG PET/CT in clinical management (within 2 months of treatment) in patients with cervical cancer at an advanced stage. Main outcome : The therapeutic impact of post therapy 18F-FDG PET/CT (within 2 months after the end of therapy) will be evaluated on the complete results included MRI. Investigators will compare : * decision of clinicians without 18F-FDG PET/CT results * and decision of clinicians knowing entire results included results of 18F-FDG PET/CT.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 40 (actual)
- First submitted
- 31 May 2019
- Start date
- 8 Jan 2020
- Primary completion date
- 5 Feb 2026
- Lead sponsor
- University Hospital, Brest
- Diseases
- Cervical cancer
- NCT number
- NCT04008095
What you commit to
- Study type: Observational
- Participants enrolled: 40
- From 8 Jan 2020 to the primary completion date, 5 Feb 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Previous history of cancer
Age
- Minor patient \< 18 years
Other
- Pregnancy or breastfeeding
- Other type of tumor than squamous cell carcinoma and adenocarcinoma
- FIGO 2019 \< IB3 or \> IVA
- Non-eligibility for the examination
- Contraindication to MRI and PET/CT
- Refusal of participation
Who the study is looking for
- Patient old ≥ 18 years
- Uterine cervical cancer with locally-advanced (FIGO 2019 IB3 to IVA)
- Histology: squamous cell carcinoma and adenocarcinoma
- Feasibility of a curative treatment
- Having formulated a non-opposition
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHRU de Brest - Hôpital Morvan Coordinator of this site? Confirm its status | Brest | France | Unknown status |
| Centre Henri Becquerel Coordinator of this site? Confirm its status | Rouen | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.